Matching Items (2)
Filtering by

Clear all filters

131774-Thumbnail Image.png

Discovering factors that drive the migration of immune cells to malignant pleural mesothelioma tumors

Description
Malignant Pleural Mesothelioma (MPM) is an aggressive deadly tumor that has few therapeutic options. Immunotherapies have shown great potential in alleviating MPM patient symptoms. Using patient data from the Cancer Genome Atlas (TCGA) we sought to identify mutations, regulators, and immune factors driving immune cell migration. We explored computational methods…

Malignant Pleural Mesothelioma (MPM) is an aggressive deadly tumor that has few therapeutic options. Immunotherapies have shown great potential in alleviating MPM patient symptoms. Using patient data from the Cancer Genome Atlas (TCGA) we sought to identify mutations, regulators, and immune factors driving immune cell migration. We explored computational methods to define regulatory causal flows in order to make biological predictions. These predictions were verified by cross-referencing peer-reviewed articles. A disease-relevant inference model was developed to examine the chemokine IL-18’s effect on natural killer cell (NK cell) migration.
ContributorsWipper, Gabrielle Frances (Author) / Plaisier, Christopher (Thesis director) / Plaisier, Seema (Committee member) / Harrington Bioengineering Program (Contributor, Contributor) / Barrett, The Honors College (Contributor)
Created2020-05
164992-Thumbnail Image.png

Applying Regulatory Networks to the Immune Landscape of Mesothelioma

Description

An immune regulatory network was constructed for the purpose of identifying target regulators in malignant pleural mesothelioma for therapies. An identified causal flow linked a mutation of D-dopachrome tautomerase to a heightened expression of regulator ASH1L and consequent down regulation of chemokine CCL5 and invasion of CD8+ T cells. Experimental…

An immune regulatory network was constructed for the purpose of identifying target regulators in malignant pleural mesothelioma for therapies. An identified causal flow linked a mutation of D-dopachrome tautomerase to a heightened expression of regulator ASH1L and consequent down regulation of chemokine CCL5 and invasion of CD8+ T cells. Experimental validation of this initial use case indicates mRNA expression of CCL5 within the tumor cells and subsequent protein expression and secretion. Further analyses will explore the migration of CD8+ T cells in response to the chemotactic CCL5.
ContributorsCook, Margaret (Author) / Plaisier, Christopher (Thesis director, Committee member) / Wilson, Melissa (Committee member) / Barrett, The Honors College (Contributor) / Harrington Bioengineering Program (Contributor) / School of Molecular Sciences (Contributor)
Created2022-05